Mifepristone challenges have hit repeated snags at Supreme Court on legal standing, and appeals court that twice ruled relaxed prescribing rules violated regulatory procedure is wary of getting overturned again.
In its original complaint, Louisiana argued the Biden administration expanded access to mifepristone without properly considering potential safety risks. The state also argued the policy violated the Comstock Act, which generally prohibits sending abortion drugs by mail.
A three-judge panel on the 5th U.S. Circuit Court of Appeals in New Orleans is poised to hear oral arguments next week in a case that could eventually restrict the nationwide distribution of the abortion drug mifepristone.
President Trump's nominee to lead the Food and Drug Administration, Dr. Heidi Overton, could force a long-delayed reckoning over the safety of the abortion drug mifepristone, but she first faces resistance from both parties in the Senate. John Mize, CEO of Americans United for Life, told Fox News Digital that Overton would bring "objectivity" to […] The post Trump's FDA pick Heidi Overton faces confirmation fight as pro-life leaders eye mifepristone crackdown appeared first on American Almanac .
President Trump's nominee to lead the Food and Drug Administration, Dr. Heidi Overton, could force a long-delayed reckoning over the safety of the abortion drug mifepristone, but she first faces resistance from both parties in the Senate. John Mize, CEO of Americans United for Life, told Fox News Digital that Overton would bring "objectivity" to the FDA's handling of mifepristone, the chemical abortion drug that now accounts for roughly two-thirds of all clinician-provided abortions in the United States. Mize said he has spoken with Overton five or six times and believes she understands the risks the drug poses to women, particularly under the current rules that allow it to be prescribed after a telehealth visit and shipped by mail…Open